These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33783020)

  • 1. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.
    Ballarini NM; Burnett T; Jaki T; Jennison C; König F; Posch M
    Stat Med; 2021 May; 40(12):2939-2956. PubMed ID: 33783020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive enrichment trials: What are the benefits?
    Burnett T; Jennison C
    Stat Med; 2021 Feb; 40(3):690-711. PubMed ID: 33244786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Bayesian modeling in frequentist adaptive enrichment designs.
    Simon N; Simon R
    Biostatistics; 2018 Jan; 19(1):27-41. PubMed ID: 28520893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian designs with frequentist and Bayesian error rate considerations.
    Wang YG; Leung DH; Li M; Tan SB
    Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familywise error control in multi-armed response-adaptive trials.
    Robertson DS; Wason JMS
    Biometrics; 2019 Sep; 75(3):885-894. PubMed ID: 30714095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing interim analysis timing for Bayesian adaptive commensurate designs.
    Wu X; Xu Y; Carlin BP
    Stat Med; 2020 Feb; 39(4):424-437. PubMed ID: 31799737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.
    Johnston SE; Lipkovich I; Dmitrienko A; Zhao YD
    Pharm Stat; 2022 Sep; 21(5):1090-1108. PubMed ID: 35322520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
    Chen N; Lee JJ
    Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity.
    Lee J; Thall PF; Msaouel P
    Biometrics; 2023 Sep; 79(3):2458-2473. PubMed ID: 35974457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The population-wise error rate for clinical trials with overlapping populations.
    Brannath W; Hillner C; Rohmeyer K
    Stat Methods Med Res; 2023 Feb; 32(2):334-352. PubMed ID: 36453057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.